Periplocymarin Suppresses Nonsmall Cell Lung Cancer Progression by Modulating MAPK14 Phosphorylation: An Integrated Multiomics and Preclinical Study
Journal of Proteome Research · 18.11.2026
DOI: 10.1021/acs.jproteome.6c00598 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Proteome Research, online erschienen am 18.11.2026. Verfasst von Xinye Wang und 10 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Graduate Research and Innovation Projects of Jiangsu Province, Jiangsu Provincial Department of Human Resources and Social Security, National Natural Science Foundation of China.
Abstract (Originalsprache)
Nonsmall cell lung cancer (NSCLC) remains a leading malignancy with limited therapies, calling for natural product-derived anticancer candidates with well-defined mechanisms. In this study, Periplocymarin was identified as a selective anti-NSCLC candidate. Its antitumor activity was verified in cell proliferation, apoptosis, migration assays and patient-derived organoid models. To dissect its antitumor mechanism, we employed an integrated strategy combining transcriptome sequencing, network pharmacology, thermal proteome profiling (TPP), microscale thermophoresis (MST) and molecular simulations, and validated the involvement of p38α MAPK (MAPK14) phosphorylation via Western blot. Finally, the in vivo antitumor efficacy and safety of Periplocymarin were validated using nude mouse xenograft and patient-derived xenograft (PDX) models. Periplocymarin inhibited proliferation and migration and induced apoptosis in NSCLC cells in a concentration-dependent manner, while also suppressing Patient-Derived Organoid (PDO) growth. Integrated analyses and experimental validation indicated MAPK14 as a candidate target associated with Periplocymarin treatment. Periplocymarin reduced MAPK14 phosphorylation, and MAPK14 knockdown partially attenuated its antitumor effects. In vivo, Periplocymarin significantly suppressed tumor growth in nude mouse subcutaneous xenograft and PDX models, with decreased Ki-67 and phospho-MAPK14 levels and no evident toxicity. This study demonstrates Periplocymarin exerts anti-NSCLC activity via modulating MAPK14 phosphorylation, supporting its further development for NSCLC therapy.
Förderung
- Graduate Research and Innovation Projects of Jiangsu Province
- Jiangsu Provincial Department of Human Resources and Social Security
- National Natural Science Foundation of China
- Nantong Municipal Health Commission
Zitieren
APA
Wang, X., Liang, X., Song, Z., Wang, M., Sun, H., Ma, X., Miao, Y., Zhou, X., Liu, Y., Shi, J., & Lv, L. (2026). Periplocymarin Suppresses Nonsmall Cell Lung Cancer Progression by Modulating MAPK14 Phosphorylation: An Integrated Multiomics and Preclinical Study. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.6c00598
Vancouver
Wang X, Liang X, Song Z, Wang M, Sun H, Ma X, et al. Periplocymarin Suppresses Nonsmall Cell Lung Cancer Progression by Modulating MAPK14 Phosphorylation: An Integrated Multiomics and Preclinical Study. Journal of Proteome Research. 2026. doi:10.1021/acs.jproteome.6c00598
BibTeX
@article{Wang2026,
author = {Wang, Xinye and Liang, Xiao and Song, Zhibin and Wang, Mingwei and Sun, Hui and Ma, Xiaoting and Miao, Yiyan and Zhou, Xingqin and Liu, Yifei and Shi, Jiahai and Lv, Liting},
title = {Periplocymarin Suppresses Nonsmall Cell Lung Cancer Progression by Modulating MAPK14 Phosphorylation: An Integrated Multiomics and Preclinical Study},
journal = {Journal of Proteome Research},
year = {2026},
doi = {10.1021/acs.jproteome.6c00598}
}
EUVIMED